{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T15:51:33Z","timestamp":1769788293280,"version":"3.49.0"},"reference-count":46,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T00:00:00Z","timestamp":1767571200000},"content-version":"vor","delay-in-days":4,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004607","name":"Guangxi Natural Science Foundation","doi-asserted-by":"publisher","award":["2022GXNSFAA035498"],"award-info":[{"award-number":["2022GXNSFAA035498"]}],"id":[{"id":"10.13039\/501100004607","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004607","name":"Guangxi Natural Science Foundation","doi-asserted-by":"publisher","award":["2023GXNSFBA026104"],"award-info":[{"award-number":["2023GXNSFBA026104"]}],"id":[{"id":"10.13039\/501100004607","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82503122"],"award-info":[{"award-number":["82503122"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82460411"],"award-info":[{"award-number":["82460411"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009329","name":"Scientific Research and Technology Development Program of Guangxi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009329","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003454","name":"Guangxi Zhuang Autonomous Region Health Department","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003454","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Immunobiology"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.imbio.2026.153155","type":"journal-article","created":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T16:59:30Z","timestamp":1767718770000},"page":"153155","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["SLAMF7 improves the efficacy of PD-1 immunotherapy by enhancing T cell response in non-small cell lung cancer"],"prefix":"10.1016","volume":"231","author":[{"given":"Juanfeng","family":"Lao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manman","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liangjian","family":"Kuang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Changliang","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhongyuan","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiongying","family":"Ling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yulin","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongjian","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liuyang","family":"Shu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.imbio.2026.153155_bb0005","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1034\/j.1600-065X.2001.1810120.x","article-title":"2B4 (CD244) and CS1: novel members of the CD2 subset of the immunoglobulin superfamily molecules expressed on natural killer cells and other leukocytes","volume":"181","author":"Boles","year":"2001","journal-title":"Immunol. Rev."},{"issue":"1","key":"10.1016\/j.imbio.2026.153155_bb0010","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1080\/1744666X.2016.1209112","article-title":"The role of SLAMF7 in multiple myeloma: impact on therapy","volume":"13","author":"Boudreault","year":"2017","journal-title":"Expert Rev. Clin. Immunol."},{"issue":"3","key":"10.1016\/j.imbio.2026.153155_bb0015","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"issue":"9","key":"10.1016\/j.imbio.2026.153155_bb0020","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abe3348","article-title":"Tumor-specific cytolytic CD4 T cells mediate immunity against human cancer","volume":"7","author":"Cachot","year":"2021","journal-title":"Sci. Adv."},{"issue":"1","key":"10.1016\/j.imbio.2026.153155_bb0025","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s13045-023-01499-1","article-title":"Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy","volume":"16","author":"Cai","year":"2023","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.imbio.2026.153155_bb0030","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1146\/annurev-immunol-030409-101302","article-title":"SLAM family receptors and SAP adaptors in immunity","volume":"29","author":"Cannons","year":"2011","journal-title":"Annu. Rev. Immunol."},{"issue":"7651","key":"10.1016\/j.imbio.2026.153155_bb0035","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/nature22076","article-title":"SLAMF7 is critical for phagocytosis of haematopoietic tumour cells via Mac-1 integrin","volume":"544","author":"Chen","year":"2017","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.imbio.2026.153155_bb0040","doi-asserted-by":"crossref","first-page":"7891","DOI":"10.3390\/curroncol30090573","article-title":"SLAMF7 as a Promising Immunotherapeutic Target in Multiple Myeloma Treatments","volume":"30","author":"Chu","year":"2023","journal-title":"Curr. Oncol."},{"issue":"16","key":"10.1016\/j.imbio.2026.153155_bb0045","doi-asserted-by":"crossref","first-page":"4373","DOI":"10.1016\/j.cell.2024.06.036","article-title":"Blockade of LAG-3 and PD-1 leads to co-expression of cytotoxic and exhaustion gene modules in CD8(+) T cells to promote antitumor immunity","volume":"187","author":"Cillo","year":"2024","journal-title":"Cell"},{"issue":"13","key":"10.1016\/j.imbio.2026.153155_bb0050","doi-asserted-by":"crossref","first-page":"3620","DOI":"10.1158\/1078-0432.CCR-20-4746","article-title":"Phase I\/Ib Clinical Trial of Sabatolimab, an Anti-TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti-PD-1 Antibody","volume":"27","author":"Curigliano","year":"2021","journal-title":"Advanced Solid Tumors. Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.imbio.2026.153155_bb0055","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1186\/s40425-019-0768-9","article-title":"The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors","volume":"7","author":"Davis","year":"2019","journal-title":"J. Immunother. Cancer"},{"issue":"6","key":"10.1016\/j.imbio.2026.153155_bb0060","doi-asserted-by":"crossref","DOI":"10.3802\/jgo.2024.35.e79","article-title":"SLAMF7 predicts prognosis and correlates with immune infiltration in serous ovarian carcinoma","volume":"35","author":"Deng","year":"2024","journal-title":"J. Gynecol. Oncol."},{"issue":"8","key":"10.1016\/j.imbio.2026.153155_bb0065","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1038\/nm730","article-title":"Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion","volume":"8","author":"Dong","year":"2002","journal-title":"Nat. Med."},{"issue":"87","key":"10.1016\/j.imbio.2026.153155_bb0070","doi-asserted-by":"crossref","first-page":"eadg1487","DOI":"10.1126\/sciimmunol.adg1487","article-title":"Lung tumor-infiltrating T(reg) have divergent transcriptional profiles and function linked to checkpoint blockade response","volume":"8","author":"Dykema","year":"2023","journal-title":"Sci Immunol"},{"key":"10.1016\/j.imbio.2026.153155_bb0075","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.ejca.2017.02.015","article-title":"iRECIST: a clarification of tumour response assessment in the immunotherapy era","volume":"77","author":"Ferte","year":"2017","journal-title":"Eur. J. Cancer"},{"issue":"22","key":"10.1016\/j.imbio.2026.153155_bb0080","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"21","key":"10.1016\/j.imbio.2026.153155_bb0085","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","article-title":"Pembrolizumab for the treatment of non-small-cell lung cancer","volume":"372","author":"Garon","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"22","key":"10.1016\/j.imbio.2026.153155_bb0090","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1801946","article-title":"Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden","volume":"378","author":"Hellmann","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"10027","key":"10.1016\/j.imbio.2026.153155_bb0095","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","article-title":"Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial","volume":"387","author":"Herbst","year":"2016","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.imbio.2026.153155_bb0100","doi-asserted-by":"crossref","first-page":"30779","DOI":"10.1038\/s41598-024-80971-5","article-title":"SLAMF7 defines subsets of human effector CD8 T cells","volume":"14","author":"Kared","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.imbio.2026.153155_bb0105","doi-asserted-by":"crossref","first-page":"10501","DOI":"10.1038\/ncomms10501","article-title":"Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints","volume":"7","author":"Koyama","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.imbio.2026.153155_bb0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2022.108813","article-title":"OX40 enhances T cell immune response to PD-1 blockade therapy in non-small cell lung cancer","volume":"108","author":"Lao","year":"2022","journal-title":"Int. Immunopharmacol."},{"issue":"3","key":"10.1016\/j.imbio.2026.153155_bb0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.imbio.2023.152391","article-title":"Peripheral changes in T cells predict efficacy of anti-PD-1 immunotherapy in non-small cell lung cancer","volume":"228","author":"Lao","year":"2023","journal-title":"Immunobiology"},{"issue":"3","key":"10.1016\/j.imbio.2026.153155_bb0120","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/s41418-024-01399-y","article-title":"SLAMF7 (CD319) on activated CD8(+) T cells transduces environmental cues to initiate cytotoxic effector cell responses","volume":"32","author":"Lingel","year":"2025","journal-title":"Cell Death Differ."},{"issue":"1","key":"10.1016\/j.imbio.2026.153155_bb0125","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1186\/s13045-017-0541-9","article-title":"Recent development in clinical applications of PD-1 and PD-L1 antibodies for cancer immunotherapy","volume":"10","author":"Liu","year":"2017","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.imbio.2026.153155_bb0130","article-title":"Real-World Outcomes of First-Line Treatment with Anti-PD(L)1-based Combination Therapy for Nonsquamous Metastatic Non-Small Cell Lung Cancer: a Multiregional Chart Review in Europe, Japan, and the United States","volume":"10","author":"Liu","year":"2024","journal-title":"JCO Glob Oncol"},{"issue":"7","key":"10.1016\/j.imbio.2026.153155_bb0135","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1505654","article-title":"Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma","volume":"373","author":"Lonial","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.imbio.2026.153155_bb0140","doi-asserted-by":"crossref","first-page":"193","DOI":"10.4049\/jimmunol.2000300","article-title":"SLAMF7 Signaling Reprograms T Cells toward Exhaustion in the Tumor Microenvironment","volume":"206","author":"O'Connell","year":"2021","journal-title":"J. Immunol."},{"issue":"1","key":"10.1016\/j.imbio.2026.153155_bb0145","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1186\/s13046-023-02846-3","article-title":"CD28\/PD1 co-expression: dual impact on CD8(+) T cells in peripheral blood and tumor tissue, and its significance in NSCLC patients' survival and ICB response","volume":"42","author":"Palermo","year":"2023","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"10","key":"10.1016\/j.imbio.2026.153155_bb0150","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1007\/s00262-022-03177-6","article-title":"Elotuzumab, a potential therapeutic humanized anti-SLAMF7 monoclonal antibody, enhances natural killer cell-mediated killing of primary effusion lymphoma cells","volume":"71","author":"Panaampon","year":"2022","journal-title":"Cancer Immunol. Immunother."},{"issue":"1","key":"10.1016\/j.imbio.2026.153155_bb0155","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s12885-022-10446-1","article-title":"Role of antiangiogenic agents in first-line treatment for advanced NSCLC in the era of immunotherapy","volume":"23","author":"Pang","year":"2023","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.imbio.2026.153155_bb0160","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.jtho.2024.09.1439","article-title":"Long-Term Survival Outcomes with First-Line Nivolumab Plus Ipilimumab-based Treatment in patients with Metastatic NSCLC and Tumor Programmed Death-Ligand 1 lower than 1%: a Pooled Analysis","volume":"20","author":"Peters","year":"2025","journal-title":"J. Thorac. Oncol."},{"issue":"7","key":"10.1016\/j.imbio.2026.153155_bb0165","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.molmed.2019.04.012","article-title":"Abandoning the Notion of Non-Small Cell Lung Cancer","volume":"25","author":"Relli","year":"2019","journal-title":"Trends Mol. Med."},{"issue":"11","key":"10.1016\/j.imbio.2026.153155_bb0170","doi-asserted-by":"crossref","first-page":"5431","DOI":"10.21873\/anticanres.15355","article-title":"SLAMF7 and TREM1 Mediate Immunogenic Cell Death in Colorectal Cancer Cells: Focus on Microsatellite Stability","volume":"41","author":"Roh","year":"2021","journal-title":"Anticancer Res"},{"issue":"5","key":"10.1016\/j.imbio.2026.153155_bb0175","doi-asserted-by":"crossref","DOI":"10.3390\/cancers17050906","article-title":"Targeting Immune Checkpoint Inhibitors for Non-Small-Cell Lung Cancer: beyond PD-1\/PD-L1 Monoclonal Antibodies","volume":"17","author":"Roussot","year":"2025","journal-title":"Cancers (Basel)"},{"issue":"3","key":"10.1016\/j.imbio.2026.153155_bb0180","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/nri.2017.108","article-title":"The diverse functions of the PD1 inhibitory pathway","volume":"18","author":"Sharpe","year":"2018","journal-title":"Nat. Rev. Immunol."},{"issue":"1","key":"10.1016\/j.imbio.2026.153155_bb0185","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/bjh.15393","article-title":"SLAMF7 (CD319\/CS1) is expressed in plasmablastic lymphoma and is a potential diagnostic marker and therapeutic target","volume":"185","author":"Shi","year":"2019","journal-title":"Br. J. Haematol."},{"issue":"7","key":"10.1016\/j.imbio.2026.153155_bb0190","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1158\/2159-8290.CD-18-0099","article-title":"STK11\/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma","volume":"8","author":"Skoulidis","year":"2018","journal-title":"Cancer Discov."},{"key":"10.1016\/j.imbio.2026.153155_bb0195","doi-asserted-by":"crossref","first-page":"6984948","DOI":"10.1155\/2018\/6984948","article-title":"Anti-PD-1\/PD-L1 Therapy for Non-Small-Cell Lung Cancer: toward Personalized Medicine and Combination strategies","volume":"2018","author":"Sui","year":"2018","journal-title":"J. Immunol. Res."},{"issue":"26","key":"10.1016\/j.imbio.2026.153155_bb0200","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.imbio.2026.153155_bb0205","doi-asserted-by":"crossref","first-page":"1429879","DOI":"10.1155\/2024\/1429879","article-title":"Elotuzumab Enhances CD16-Independent NK Cell-Mediated Cytotoxicity against Myeloma Cells by Upregulating several NK Cell-Enhancing Genes","volume":"2024","author":"Wang","year":"2024","journal-title":"J. Immunol. Res."},{"issue":"11","key":"10.1016\/j.imbio.2026.153155_bb0210","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1158\/0008-5472.CAN-23-3106","article-title":"Repolarization of Immunosuppressive Macrophages by Targeting SLAMF7-Regulated CCL2 Signaling Sensitizes Hepatocellular Carcinoma to Immunotherapy","volume":"84","author":"Weng","year":"2024","journal-title":"Cancer Res."},{"issue":"6","key":"10.1016\/j.imbio.2026.153155_bb0215","doi-asserted-by":"crossref","DOI":"10.1172\/JCI150224","article-title":"SLAMF7 regulates the inflammatory response in macrophages during polymicrobial sepsis","volume":"133","author":"Wu","year":"2023","journal-title":"J. Clin. Invest."},{"issue":"10","key":"10.1016\/j.imbio.2026.153155_bb0220","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1007\/s12094-024-03442-3","article-title":"Comparison of efficacy and safety of PD-1\/PD-L1 combination therapy in first-line treatment of advanced NSCLC: an updated systematic review and network meta-analysis","volume":"26","author":"Yang","year":"2024","journal-title":"Clin. Transl. Oncol."},{"key":"10.1016\/j.imbio.2026.153155_bb0225","doi-asserted-by":"crossref","DOI":"10.1177\/17534259251326700","article-title":"Emerging roles of SLAMF7 in immune cells and related diseases","volume":"31","author":"Zhang","year":"2025","journal-title":"Innate Immun."},{"issue":"8","key":"10.1016\/j.imbio.2026.153155_bb0230","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1158\/2326-6066.CIR-23-1102","article-title":"Multifunctional Bispecific Nanovesicles Targeting SLAMF7 Trigger Potent Antitumor Immunity","volume":"12","author":"Zhu","year":"2024","journal-title":"Cancer Immunol. Res."}],"container-title":["Immunobiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S017129852600001X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S017129852600001X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T01:40:48Z","timestamp":1769737248000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S017129852600001X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S017129852600001X"],"URL":"https:\/\/doi.org\/10.1016\/j.imbio.2026.153155","relation":{},"ISSN":["0171-2985"],"issn-type":[{"value":"0171-2985","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SLAMF7 improves the efficacy of PD-1 immunotherapy by enhancing T cell response in non-small cell lung cancer","name":"articletitle","label":"Article Title"},{"value":"Immunobiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.imbio.2026.153155","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier GmbH.","name":"copyright","label":"Copyright"}],"article-number":"153155"}}